Nanologica AB (publ) (NICA.ST)
SEK 0.84
(0.48%)
SEK 0.84
(0.48%)
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2023 | 1.44 Million SEK | -7.2% |
| 2022 | 1.55 Million SEK | -87.96% |
| 2021 | 12.91 Million SEK | -19.96% |
| 2020 | 16.13 Million SEK | 57.77% |
| 2019 | 10.22 Million SEK | 146.71% |
| 2018 | 4.14 Million SEK | 59.44% |
| 2017 | 2.59 Million SEK | 29.97% |
| 2016 | 2 Million SEK | -38.69% |
| 2015 | 3.26 Million SEK | 98.3% |
| 2014 | 1.64 Million SEK | -65.28% |
| 2013 | 4.73 Million SEK | 32.98% |
| 2012 | 3.56 Million SEK | 0.0% |
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2024 Q1 | 5.03 Million SEK | 6616.0% |
| 2024 Q2 | 2.17 Million SEK | -56.84% |
| 2023 Q1 | 355 Thousand SEK | -47.33% |
| 2023 Q3 | 342 Thousand SEK | -49.11% |
| 2023 Q2 | 672 Thousand SEK | 89.3% |
| 2023 FY | 1.44 Million SEK | -7.2% |
| 2023 Q4 | 75 Thousand SEK | -78.07% |
| 2022 Q3 | 401 Thousand SEK | 90.95% |
| 2022 Q2 | 210 Thousand SEK | -22.22% |
| 2022 FY | 1.55 Million SEK | -87.96% |
| 2022 Q1 | 270 Thousand SEK | -60.06% |
| 2022 Q4 | 674 Thousand SEK | 68.08% |
| 2021 Q1 | 5.62 Million SEK | 5.66% |
| 2021 FY | 12.91 Million SEK | -19.96% |
| 2021 Q2 | 4.49 Million SEK | -20.01% |
| 2021 Q4 | 676 Thousand SEK | -68.1% |
| 2021 Q3 | 2.11 Million SEK | -52.88% |
| 2020 Q1 | 3.9 Million SEK | 30.97% |
| 2020 FY | 16.13 Million SEK | 57.77% |
| 2020 Q4 | 5.32 Million SEK | 127.49% |
| 2020 Q2 | 4.57 Million SEK | 17.09% |
| 2020 Q3 | 2.33 Million SEK | -48.83% |
| 2019 FY | 10.22 Million SEK | 146.71% |
| 2019 Q3 | 2.01 Million SEK | -32.23% |
| 2019 Q2 | 2.96 Million SEK | 30.6% |
| 2019 Q1 | 2.27 Million SEK | -0.23% |
| 2019 Q4 | 2.98 Million SEK | 48.3% |
| 2018 Q1 | 418 Thousand SEK | -82.6% |
| 2018 Q2 | 386 Thousand SEK | -7.66% |
| 2018 Q3 | 1.06 Million SEK | 175.91% |
| 2018 Q4 | 2.27 Million SEK | 113.74% |
| 2018 FY | 4.14 Million SEK | 59.44% |
| 2017 Q2 | 373 Thousand SEK | 4044.44% |
| 2017 FY | 2.59 Million SEK | 29.97% |
| 2017 Q4 | 2.4 Million SEK | 1164.13% |
| 2017 Q3 | 190 Thousand SEK | -49.06% |
| 2017 Q1 | 9000.00 SEK | -99.41% |
| 2016 Q1 | 734 Thousand SEK | 9.12% |
| 2016 FY | 2 Million SEK | -38.69% |
| 2016 Q4 | 1.51 Million SEK | 244.63% |
| 2016 Q3 | 440 Thousand SEK | 900.0% |
| 2016 Q2 | 44 Thousand SEK | -94.01% |
| 2015 Q4 | 672.65 Thousand SEK | -37.02% |
| 2015 Q1 | 1.93 Million SEK | 52.07% |
| 2015 Q2 | 656 Thousand SEK | -66.1% |
| 2015 FY | 3.26 Million SEK | 98.3% |
| 2015 Q3 | 1.06 Million SEK | 62.8% |
| 2014 Q4 | 1.27 Million SEK | 0.0% |
| 2014 Q2 | 2.04 Million SEK | 0.0% |
| 2014 Q1 | 2.04 Million SEK | 0.0% |
| 2014 FY | 1.64 Million SEK | -65.28% |
| 2014 Q3 | 1.27 Million SEK | -37.76% |
| 2013 FY | 4.73 Million SEK | 32.98% |
| 2012 FY | 3.56 Million SEK | 0.0% |
| Name | Revenue | Revenue Difference |
|---|---|---|
| Alzinova AB (publ) | 270 Thousand SEK | -434.444% |
| Amniotics AB (publ) | - SEK | -Infinity% |
| Asarina Pharma AB (publ) | - SEK | -Infinity% |
| BioArctic AB (publ) | 615.99 Million SEK | 99.766% |
| Calliditas Therapeutics AB (publ) | 1.2 Billion SEK | 99.88% |
| Genovis AB (publ.) | 158.23 Million SEK | 99.088% |
| LIDDS AB (publ) | - SEK | -Infinity% |
| Magle Chemoswed Holding AB (publ) | 170.44 Million SEK | 99.153% |
| OncoZenge AB (publ) | 3000.00 SEK | -48000.0% |
| Saniona AB (publ) | 16.84 Million SEK | 91.431% |
| Simris Alg AB (publ) | 4.35 Million SEK | 66.858% |
| Vicore Pharma Holding AB (publ) | - SEK | -Infinity% |
| AcouSort AB (publ) | 10.55 Million SEK | 86.324% |
| Active Biotech AB (publ) | - SEK | -Infinity% |
| Camurus AB (publ) | 1.71 Billion SEK | 99.916% |
| Cantargia AB (publ) | - SEK | -Infinity% |
| Scandinavian ChemoTech AB (publ) | 2.82 Million SEK | 48.866% |
| Guard Therapeutics International AB (publ) | - SEK | -Infinity% |
| Mendus AB (publ) | 28.48 Million SEK | 94.935% |
| Kancera AB (publ) | 1.03 Million SEK | -39.42% |
| Karolinska Development AB (publ) | 2.01 Million SEK | 28.352% |
| Lipum AB (publ) | 53 Thousand SEK | -2622.642% |
| Lipigon Pharmaceuticals AB (publ) | 16.4 Million SEK | 91.205% |
| NextCell Pharma AB | 10.66 Million SEK | 86.469% |
| Xbrane Biopharma AB (publ) | 238.72 Million SEK | 99.396% |
| Xintela AB (publ) | 78 Thousand SEK | -1750.0% |
| Ziccum AB (publ) | 3.74 Million SEK | 61.489% |
| Elicera Therapeutics AB (publ) | 11.23 Million SEK | 87.151% |
| Modus Therapeutics Holding AB (publ) | - SEK | -Infinity% |
| Isofol Medical AB (publ) | 721 Thousand SEK | -100.139% |
| Xspray Pharma AB (publ) | - SEK | -Infinity% |
| CombiGene AB (publ) | 5.54 Million SEK | 73.972% |
| Diamyd Medical AB (publ) | 130 Thousand SEK | -1010.0% |
| Intervacc AB (publ) | 8.01 Million SEK | 81.996% |
| Alligator Bioscience AB (publ) | 58.1 Million SEK | 97.517% |
| Sprint Bioscience AB (publ) | 50.48 Million SEK | 97.142% |
| QuiaPEG Pharmaceuticals Holding AB (publ) | 4.37 Million SEK | 67.01% |
| Corline Biomedical AB | 25.03 Million SEK | 94.235% |
| IRLAB Therapeutics AB (publ) | 5.67 Million SEK | 74.586% |
| Bio-Works Technologies AB (publ) | 43.89 Million SEK | 96.713% |
| Aptahem AB (publ) | 2.63 Million SEK | 45.147% |
| Infant Bacterial Therapeutics AB (publ) | 77 Thousand SEK | -1774.026% |
| Fluicell AB (publ) | 3.33 Million SEK | 56.771% |
| Biovica International AB (publ) | 7.29 Million SEK | 80.206% |
| Spago Nanomedical AB (publ) | 1.2 Million SEK | -19.95% |
| Abliva AB (publ) | 137 Thousand SEK | -953.285% |
| Egetis Therapeutics AB (publ) | 57.6 Million SEK | 97.495% |
| 2cureX AB (publ) | 155 Thousand SEK | -830.968% |
| I-Tech AB | 120.86 Million SEK | 98.806% |
| Hansa Biopharma AB (publ) | 134.09 Million SEK | 98.924% |
| Cyxone AB (publ) | 5.14 Million SEK | 71.97% |
| ExpreS2ion Biotech Holding AB (publ) | 7.05 Million SEK | 79.532% |
| Biosergen AB | - SEK | -Infinity% |
| SynAct Pharma AB | - SEK | -Infinity% |
| Annexin Pharmaceuticals AB (publ) | - SEK | -Infinity% |
| BioInvent International AB (publ) | 71.46 Million SEK | 97.981% |
| Stayble Therapeutics AB (publ) | - SEK | -Infinity% |
| Oncopeptides AB (publ) | 35.22 Million SEK | 95.903% |
| Pila Pharma AB (publ) | 1.46 Million SEK | 1.368% |
| Ascelia Pharma AB (publ) | - SEK | -Infinity% |
| Diagonal Bio AB (publ) | 23 Thousand SEK | -6173.913% |